JP2013531679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531679A5 JP2013531679A5 JP2013518765A JP2013518765A JP2013531679A5 JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5 JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulation
- seq
- amino acid
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36120910P | 2010-07-02 | 2010-07-02 | |
| US61/361,209 | 2010-07-02 | ||
| PCT/US2011/042838 WO2012003470A2 (en) | 2010-07-02 | 2011-07-01 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Division JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013531679A JP2013531679A (ja) | 2013-08-08 |
| JP2013531679A5 true JP2013531679A5 (enExample) | 2014-08-14 |
Family
ID=45402685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518765A Pending JP2013531679A (ja) | 2010-07-02 | 2011-07-01 | 抗体製剤 |
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754195B2 (enExample) |
| EP (1) | EP2588141A4 (enExample) |
| JP (2) | JP2013531679A (enExample) |
| CN (1) | CN103108658B (enExample) |
| AU (2) | AU2011274363A1 (enExample) |
| BR (1) | BR112012033457A2 (enExample) |
| CA (1) | CA2803998A1 (enExample) |
| SG (1) | SG186421A1 (enExample) |
| WO (1) | WO2012003470A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| MA37777B1 (fr) * | 2012-06-21 | 2017-07-31 | Ucb Pharma Sa | Préparation pharmaceutique |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| EP3626742A1 (en) * | 2013-09-27 | 2020-03-25 | F. Hoffmann-La Roche AG | Anti-pdl1 antibody formulations |
| JP6799904B2 (ja) * | 2014-07-31 | 2020-12-16 | キユーピー株式会社 | 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法 |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| ES2970186T3 (es) | 2015-11-25 | 2024-05-27 | Immunogen Inc | Formulaciones farmacéuticas y métodos de uso de las mismas |
| WO2017095848A1 (en) | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| WO2017106716A1 (en) | 2015-12-16 | 2017-06-22 | Regeneron Pharmaceuticals, Inc. | Compositions and methods of manufacturing protein microparticles |
| CN105920600A (zh) * | 2016-04-19 | 2016-09-07 | 上海景泽生物技术有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| CN113474360B (zh) | 2019-02-18 | 2025-01-07 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP4271412A4 (en) | 2020-12-30 | 2024-12-04 | Ammax Bio, Inc | Extended local release of antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0869177B1 (en) | 1989-02-09 | 2008-06-04 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Polyclonal antibody against the human alpha pdgf receptor and use thereof |
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| WO1992013867A1 (en) | 1991-01-31 | 1992-08-20 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
| IE920318A1 (en) | 1991-01-31 | 1992-07-29 | Univ California | Human platelet-derived growth factor receptors |
| US5444151A (en) | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| PT2275119E (pt) * | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| AU1344102A (en) * | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| CN101721362B (zh) * | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| AU2003298799A1 (en) | 2002-12-02 | 2004-06-23 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2005087269A1 (ja) | 2004-03-16 | 2005-09-22 | Dnavec Research Inc. | 腫瘍増殖を抑制する方法 |
| NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
| WO2006138729A2 (en) * | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
| AU2007260769A1 (en) * | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| EP2081553B1 (en) * | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
| US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
-
2011
- 2011-07-01 JP JP2013518765A patent/JP2013531679A/ja active Pending
- 2011-07-01 CA CA2803998A patent/CA2803998A1/en not_active Abandoned
- 2011-07-01 BR BR112012033457A patent/BR112012033457A2/pt not_active IP Right Cessation
- 2011-07-01 US US13/175,522 patent/US8754195B2/en not_active Expired - Fee Related
- 2011-07-01 SG SG2012094074A patent/SG186421A1/en unknown
- 2011-07-01 WO PCT/US2011/042838 patent/WO2012003470A2/en not_active Ceased
- 2011-07-01 AU AU2011274363A patent/AU2011274363A1/en not_active Abandoned
- 2011-07-01 CN CN201180042125.5A patent/CN103108658B/zh not_active Expired - Fee Related
- 2011-07-01 EP EP11801508.0A patent/EP2588141A4/en not_active Withdrawn
-
2015
- 2015-08-26 JP JP2015166305A patent/JP2016026164A/ja active Pending
-
2016
- 2016-02-29 AU AU2016201291A patent/AU2016201291A1/en not_active Abandoned